Customer No.: 26308 *Patent*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pettersson et al Attorney Docket No.: 9404.20834

Serial No.: 10/531,598 Examiner: Micah-Paul Young

Filed: November 25, 2005 Group Art Unit: 1618

Title: Gastric Acid Secretion Inhibition Composition

PAYMENT OF BASE ISSUE FEE
SUMMARY OF INTERVIEW

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

The Notice of Allowance and Fee(s) Due was mailed March 23, 2010. Included with the Notice was an Examiner's Amendment and an Interview Summary regarding a telephonic interview conducted February 25, 2010, during which authorization for the Examiner's Amendment was given, placing the claims in condition for allowance.

Payment of the Base Issue Fee accompanies this submission, which includes a Summary of the Interview.

REMARKS

The Examiner's time and attention during a telephonic interview conducted February 25, 2010 are acknowledged and appreciated. Also present at the interview were the Examiner's Supervisor Michael Hartley and the undersigned attorney.

During the interview, the Examiner and the undersigned attorney discussed an amendment to application claim 49 to overcome Goldman US 5,204,118, by adding the terminology "suffering from GERD" after "human" and by changing "comprising" to "consisting essentially of," as follows:

49 (Amended). A method for treating at least one symptom of gastro-esophageal reflux disease (GERD) in a human suffering from GERD ~~comprising~~ consisting essentially of

(i) identifying a proton pump inhibitor (PPI) selected from a group consisting of lansoprazole, omeprazole, pantoprazole, rabeprazole, pariprazole, leminoprazole, and their pharmaceutically acceptable salts, isomers including enantiomers, and pharmaceutically acceptable salts of said isomers,

(ii) identifying an H2 receptor antagonist (H2RA) selected from a group consisting of cimetidine, ranitidine, nizatidine and famotidine, and their pharmaceutically acceptable salts, isomers, and pharmaceutically acceptable salts of said isomers,

(iii) adopting an oral dose regime comprising:

(a) selecting an oral dosage form for the H2RA for release of H2RA in a gastro-intestinal tract;

(b) selecting an oral dosage form for the PPI for release of PPI in the gastro-intestinal tract and that, when orally administered to the gastro-intestinal tract concurrently with the H2RA, delays and/or extends the release of the PPI relative to the release of the H2RA;

(iv) orally administering the selected oral dosage forms of the PPI and the H2RA concurrently according to the dose regime to affect a rise in gastric pH to above about 3 within about 2 hours of administration, thereby treating at least one symptom of GERD promptly, optionally with an antacid agent or an alginate, and

(v) repeating (iv), if necessary over a prolonged period until 6 hours from the administration of the last dose.

wherein the at least one symptom of GERD is selected from a group consisting of heartburn, sour stomach, and upper abdominal pain.

During the interview, the undersigned attorney also suggested the inclusion of the terminology "optionally with an antacid agent or alginate" found in the claim above.

During the interview, the undersigned attorney authorized the entry of the above amendment to claim 49.

During the interview, the undersigned attorney also suggested the following amendment to application claim 116, to harmonize the claim with "optionally with an antacid or alginate" terminology in amended claim 49:

116 (Amended). A method as claimed in claim 49, wherein at least one of the selected oral dosage forms ~~further comprises an~~ contains the antacid agent or ~~an~~ the alginate.

Both amendments are accurately reflected in the Examiner's Amendment that accompanied the Notice of Allowance and Fee(s) Due. Applicant herewith submits the Base Issue Fee.

Respectfully Submitted,

By _____
Daniel D. Ryan, Reg. No. 29,243

RYAN KROMHOLZ & MANION, S.C.
Post Office Box 26618
Milwaukee, Wisconsin 53226
(262) 783 - 1300
Customer No.: 26308